Neuraminidase inhibitors for preventing and treating influenza in healthy adults
Jefferson, Tom; Jones, Mark; Doshi, Peter; Del Mar, Chris

Published in: British Medical Journal

DOI: 10.1136/bmj.b5106

Published: 08/12/2009

Document Version: Publisher's PDF, also known as Version of record

Link to publication in Bond University research repository.

Recommended citation (APA):

General rights
Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

For more information, or if you believe that this document breaches copyright, please contact the Bond University research repository coordinator.
Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis

Tom Jefferson, researcher; Mark Jones, statistician; Peter Doshi, doctoral student; Chris Del Mar, dean; coordinating editor of Cochrane Acute Respiratory Infections Group

ABSTRACT

Objectives To update a 2005 Cochrane review that assessed the effects of neuraminidase inhibitors in preventing or ameliorating the symptoms of influenza, the transmission of influenza, and complications from influenza in healthy adults, and to estimate the frequency of adverse effects.


Selection criteria Randomised placebo controlled studies of neuraminidase inhibitors in otherwise healthy adults exposed to naturally occurring influenza.

Main outcome measures Duration and incidence of symptoms; incidence of lower respiratory tract infections, or their proxies; and adverse events.

Data extraction Two reviewers applied inclusion criteria, assessed trial quality, and extracted data.

Data analysis Comparisons were structured into prophylaxis, treatment, and adverse events, with further subdivision by outcome and dose.

Results 20 trials were included: four on prophylaxis, 12 on treatment, and four on postexposure prophylaxis. For prophylaxis, neuraminidase inhibitors had no effect against influenza-like illness or asymptomatic influenza. The efficacy of oral oseltamivir against symptomatic laboratory confirmed influenza was 61% (risk ratio 0.39, 95% confidence interval 0.18 to 0.85) at 75 mg daily and 73% (0.27, 0.11 to 0.67) at 150 mg daily. Inhaled zanamivir 10 mg daily was 62% efficacious (0.38, 0.17 to 0.85). Oseltamivir for postexposure prophylaxis had an efficacy of 58% (95% confidence interval 15% to 79%) and 84% (49% to 95%) in two trials of households. Zanamivir performed similarly. The hazard ratios for time to alleviation of influenza-like illness symptoms were in favour of treatment: 1.20 (95% confidence interval 1.06 to 1.35) for oseltamivir and 1.24 (1.13 to 1.36) for zanamivir. Eight unpublished studies on complications were ineligible and therefore excluded. The remaining evidence suggests oseltamivir did not reduce influenza related lower respiratory tract complications (risk ratio 0.55, 95% confidence interval 0.22 to 1.35). From trial evidence, oseltamivir induced nausea (odds ratio 1.79, 95% confidence interval 1.10 to 2.93). Evidence of rarer adverse events from pharmacovigilance was of poor quality or possibly under-reported.

Conclusion Neuraminidase inhibitors have modest effectiveness against the symptoms of influenza in otherwise healthy adults. The drugs are effective postexposure against laboratory confirmed influenza, but this is a small component of influenza-like illness, so for this outcome neuraminidase inhibitors are not effective. Neuraminidase inhibitors might be regarded as optional for reducing the symptoms of seasonal influenza. Pauclity of good data has undermined previous findings for oseltamivir’s prevention of complications from influenza. Independent randomised trials to resolve these uncertainties are needed.

INTRODUCTION

Neuraminidase inhibitors comprise nebulised zanamivir (Relenza; Glaxo Wellcome) and oral oseltamivir (Tamiflu; Gilead Sciences and F Hoffmann-La Roche), and others still under development for parenteral or long acting use. Inhibiting neuraminidase—which, as with haemagglutinin, is specific to influenza—blocks the exit of the influenza virus from the host cell, thereby preventing replication in other than a few host cells.

The use of neuraminidase inhibitors has increased dramatically with the spread of the influenza A/H1N1 pandemic that began in April 2009, a novel and potentially serious infection. Partly because of the rise in resistance to amantadine and rimantadine and the lack of an effective vaccine, neuraminidase inhibitors became a widespread public health intervention. Their use for early containment and interruption was also recommended in many pandemic plans, and the World Health Organization had previously encouraged member countries to gain experience with them.
more of patients aged 14-60 (excluding older people at higher risk of complications). The updated search is summarised in the web extra. It included checking the references of other systematic reviews.4 5 9 10

Two of us separately read all titles and studies retrieved in the search and applied inclusion criteria. Disagreements were resolved by discussion with a third reviewer. Data were extracted on to standard forms, checked, and recorded. Assessing for risk of bias (using established criteria)11 became a major focus of this review.

Among complications we included a combined outcome of pneumonia, bronchitis, sinusitis, and otitis media requiring antibiotics in people with laboratory confirmed influenza. We were unable to meta-analyse the same outcomes reported by Kaiser et al10 because the data for those outcomes were not available to us for individual trials. We carried out a sensitivity analysis of complications by excluding the unpublished trials included in the Kaiser review criticised by Hayashi.

We used random effects methods to compare dichotomous outcomes (risk ratio for efficacy and odds ratio for safety); therefore estimates meta-analysed over multiple trials are average treatment effects. Where hazard ratios were not provided we converted the ratio of medians of treatment groups into (log) hazard ratios (estimating the variance of these)12 to enable meta-analysis of time to event outcomes.

We carried out an additional search for evidence of harms, including submitting a Freedom of Information Act request to the US Food and Drug Administration for all data on the harms of oseltamivir and zanamivir.13 We also pursued authors of some papers and manufacturers in attempts to disentangle summarised or conflated data.

METHODS

We updated a search previously undertaken in any language for randomised or quasirandomised studies that compared oseltamivir or zanamivir in otherwise healthy people exposed to naturally occurring influenza, against placebo, control antivirals, or no intervention (or compared doses or schedules of the neuraminidase inhibitors) with the outcomes of influenza (efficacy) or influenza-like illness (effectiveness).6 We excluded experimental influenza challenge studies as their generalisability and comparability with field studies is uncertain. Studies had to include 75% or

Although several systematic reviews of the effects of neuraminidase inhibitors are published, none systematically investigated the potential harms of the drugs.4 9 In addition, our previous Cochrane review6 summary of the evidence on the effects of oseltamivir on lower respiratory tract complications was criticised by Hayashi through the public Cochrane reviews feedback mechanism (see web extra on bmj.com). This criticism centred on one paper in particular, a meta-analysis of the effects of oseltamivir on complications of influenza.10 Only two of 10 randomised sets of data had been published, and Hayashi was concerned that information was insufficient to assess methods, reliability, and applicability of the eight remaining datasets.

In updating our review we addressed these additional concerns while answering the original questions: what is the evidence on the effects of neuraminidase inhibitors in preventing or ameliorating influenza, transmission of the virus, and influenza related complications in otherwise healthy adults, and what is the frequency of adverse effects? Our original review had found positive evidence on all of these effects, and gastrointestinal harms.

**Fig 1** Flow of studies identified from 2009 update of randomised controlled trials

**Fig 2** Flow of studies identified from search for evidence from post-marketing studies (excluding adverse event reporting system)
RESULTS

Overall, 29 studies made up of 10 effectiveness and 10 safety studies (six were identified by both searches) were excluded, together with a further three effectiveness studies, excluded after more deliberation (figs 1 and 2). This left 20 included trials in 19 publications. Two studies that were excluded from the effectiveness outcome question were included in the safety data sources. (See web extra for details of the included and excluded studies.)

Quality of evidence

On the basis of the published text only five trials were judged adequate by usual Cochrane Collaboration methods: one trial on prophylaxis and four on treatment. Most of the trials were at risk of bias, arising from poor descriptions of the methods, such as no description of losses to follow-up and blinding. Attempts to deal with these shortcomings were unsuccessful: although three of five first authors of studies on oseltamivir treatment responded to our contact, none had original data and referred us to the manufacturer (Roche), which was not able to unconditionally provide the information as quickly as we needed it to update this review. One meta-analysis was made up of data from 10 studies. We were obliged to exclude this meta-analysis because we were unable to determine the number of healthy adults experiencing complications in each study (some studies contained mixed populations of healthy and comorbid participants), nor the number of patients experiencing one or more of “bronchitis, lower respiratory tract infection, or pneumonia” presenting to each study.

Evidence of benefits

Prophylaxis against influenza

We found no new studies of benefit fulfilling our criteria. Two trials compared a total of 697 adults treated with inhaled zanamivir 10 mg daily and 602 with placebo (followed for 22 days), and two trials compared 675 adults treated with oral oseltamivir 75 mg daily and 413 with placebo (followed for 49 days). Evidence was insufficient to support or refute the effect of neuraminidase inhibitors on prophylaxis of influenza-like illness: risk ratio 1.28 (95% confidence interval 0.45 to 3.66) for oseltamivir and 1.51 (0.77 to 2.95) for zanamivir. Higher dosages made no difference, although this conclusion is based on a single study with only nine events (fig 3).

Zanamivir reduced the chance of symptomatic laboratory confirmed influenza (0.38, 0.17 to 0.85 for 10 mg daily). Oseltamivir was similarly efficacious (0.39, 0.18 to 0.85 for 75 mg daily; fig 4). Neither protected against asymptomatic influenza.

Postexposure prophylaxis against influenza

Postexposure prophylaxis against influenza entails giving exposed people neuraminidase inhibitors before symptoms develop. Two zanamivir trials reported significant protection for households (risk ratios 0.19 and 0.219) and two oseltamivir trials reported similar results (0.164 and 0.42).

Treatment

Eight trials of zanamivir treatment were included in the current review, of which two were linked to others (a total of 1878 participants in the treatment arm and 1310 controls, with a mean length of follow-up of 26 days). Five trials of oseltamivir were also included, one with supplementary outcome data from previous trials and another linked to a redundant publication (totalling 1118 participants in the treatment arm and 679 controls, with a mean length of follow-up of 21 days).

There was evidence of benefit in shortening the duration of influenza-like illness for zanamivir (hazard

null
RESEARCH

**Fig 4** Effect of neuraminidase inhibitors compared with placebo on prophylaxis against laboratory confirmed influenza

<table>
<thead>
<tr>
<th>No of events/Total No of participants</th>
<th>Neuraminidase inhibitors</th>
<th>Placebo</th>
<th>Risk ratio (random effects) (95% CI)</th>
<th>Weight (%)</th>
<th>Risk ratio (random effects) (95% CI)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oral oseltamivir 75 mg daily</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hayden 1999[^16]</td>
<td>6/520</td>
<td>12/259</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kashiwagi 2000[^22]</td>
<td>9/155</td>
<td>16/153</td>
<td>11.9</td>
<td>0.25 (0.09 to 0.66)</td>
<td></td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>675</td>
<td>412</td>
<td>14.5</td>
<td>0.56 (0.25 to 1.22)</td>
<td></td>
</tr>
<tr>
<td>Heterogeneity: $\chi^2=0.12, \chi^2=1.59$, df=1, P=0.21, $\tau^2=37%$</td>
<td></td>
<td></td>
<td>26.4</td>
<td>0.39 (0.18 to 0.85)</td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: z=2.36, P=0.02</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Oral oseltamivir 150 mg daily</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hayden 1999[^16]</td>
<td>7/520</td>
<td>13/260</td>
<td>12.7</td>
<td>0.27 (0.11 to 0.67)</td>
<td></td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>520</td>
<td>260</td>
<td>12.7</td>
<td>0.27 (0.11 to 0.67)</td>
<td></td>
</tr>
<tr>
<td>Heterogeneity: Not applicable</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: z=2.84, P=0.005</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inhaled zanamivir 10 mg daily</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kaiser 2000[^37]</td>
<td>16/144</td>
<td>9/48</td>
<td>15.0</td>
<td>0.59 (0.28 to 1.25)</td>
<td></td>
</tr>
<tr>
<td>Monto 1999[^30]</td>
<td>14/553</td>
<td>53/554</td>
<td>17.9</td>
<td>0.26 (0.15 to 0.47)</td>
<td></td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>697</td>
<td>602</td>
<td>32.9</td>
<td>0.38 (0.17 to 0.85)</td>
<td></td>
</tr>
<tr>
<td>Heterogeneity: $\chi^2=0.22, \chi^2=2.90$, df=1, P=0.09, $\tau^2=66%$</td>
<td></td>
<td></td>
<td>12.7</td>
<td>0.27 (0.11 to 0.67)</td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: z=2.35, P=0.02</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Intranasal zanamivir 6.4 mg daily</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kaiser 2000[^37]</td>
<td>26/141</td>
<td>9/48</td>
<td>16.2</td>
<td>1.06 (0.54 to 2.08)</td>
<td></td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>141</td>
<td>48</td>
<td>16.2</td>
<td>1.06 (0.54 to 2.08)</td>
<td></td>
</tr>
<tr>
<td>Heterogeneity: Not applicable</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: z=0.17, P=0.87</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Inhaled and intranasal zanamivir 10 mg and 6.4 mg daily</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Kaiser 2000[^37]</td>
<td>6/146</td>
<td>9/48</td>
<td>11.8</td>
<td>0.22 (0.08 to 0.58)</td>
<td></td>
</tr>
<tr>
<td>Subtotal (95% CI)</td>
<td>146</td>
<td>48</td>
<td>11.8</td>
<td>0.22 (0.08 to 0.58)</td>
<td></td>
</tr>
<tr>
<td>Heterogeneity: Not applicable</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: z=3.04, P=0.002</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Total (95% CI)</td>
<td>2179</td>
<td>1370</td>
<td>100.0</td>
<td>0.41 (0.25 to 0.65)</td>
<td></td>
</tr>
<tr>
<td>Total events</td>
<td>86</td>
<td>121</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Heterogeneity: $\chi^2=0.23, \chi^2=14.80$, df=6, P=0.02, $\tau^2=59%$</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Test for overall effect: z=3.80, P&lt;0.001</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

ratio 1.24, 95% confidence interval 1.13 to 1.36) and for oseltamivir (1.20, 1.06 to 1.35; fig 5) if taken within 48 hours of the onset of symptoms.

Data on the effectiveness of oseltamivir against complications of influenza principally came from one study,^10 as pointed out by Hayashi (see web extra). This was a meta-analysis of 10 trials containing a mixture of published and unpublished data, two of which are reported in this update and the remainder inaccessible to proper scrutiny, so that we are now obliged to disregard them. The remaining data showed no benefit for oseltamivir against complications (fig 6).

**Evidence on harms of neuraminidase inhibitors**

Two of the studies excluded for addressing the benefits of neuraminidase inhibitors question nevertheless provided information on the harms of oseltamivir.\(^{14,15}\) Eighteen safety studies were included. This left 20 included trials in 19 publications.\(^{16-34}\) We also examined two sources of pharmacovigilance data describing reported adverse events from the FDA adverse event reporting system (AERS), one obtained by request using the Freedom of Information Act, “AERS-1”, and another accessed directly from two FDA websites, “AERS-2”.\(^{39,40}\) Another dataset containing reports of adverse events was located on a website by the Japanese Pharmaceuticals and Medical Devices Agency.\(^{31}\) We were unable to gain the same access to data from the European Medicines Agency.\(^{42}\) The table summarises the characteristics of the data sources.

**Quality of evidence**

In total, 1416 titles were found, most for oseltamivir, and we discarded all except for 20 studies of different design, the two sources of pharmacovigilance data from the AERS, and the Japanese data.\(^{19,30-41}\) The Japanese data contained tables of adverse events occurring in manufacturer funded clinical trials, and included individual patient level data.

Both FDA datasets include post-licensure adverse event reports (voluntary and mandatory) from a variety of sources, including consumers, healthcare providers, and manufacturer. Reports in the FDA AERS database are of three types: “expedited (15-day)” and “periodic,” which are mandatory reports from manufacturers, and “direct,” which are reports voluntarily submitted by non-manufacturers. The two manufacturer channels comprised 2062/2275 (90.6%) of all reports on oseltamivir from the AERS. All adverse events that are “both serious and unexpected” must, according to FDA rules, be reported by manufacturers within 15 days of initial receipt of information about the event. “Serious,” by the FDA’s definition, are those events that result in “Death, a life-threatening adverse drug experience, inpatient hospitalization or prolongation of existing hospitalization, a persistent or significant disability/incapacity, or a congenital anomaly/birth defect.”\(^{43}\) For all other adverse events, reporting requirements differ on the basis of the origin of the information. Not all notices of adverse events received by the FDA are necessarily entered into the AERS.

The Japanese data contained tables of adverse events, including individual patient level data for serious adverse events.\(^{14}\) However, these were discarded because of irreconcilable differences in serious adverse events reported here but apparently not reported in two published trials.\(^{31,33}\)

**Evidence of harms**

The trials identified only one serious adverse event\(^{31}\) (so labelled in the Japanese data, a patient with neutropenia), and, in particular, no neuropsychiatric events. Oseltamivir induced nausea (odds ratio 1.79, 95% confidence interval 1.24 to 2.62; fig 5) and for oseltamivir (2.84, 1.06 to 7.15; fig 5) if taken within 48 hours of the onset of symptoms.

Data on the effectiveness of oseltamivir against complications of influenza principally came from one study,\(^{10}\) as pointed out by Hayashi (see web extra). This was a meta-analysis of 10 trials containing a mixture of published and unpublished data, two of which are reported in this update and the remainder inaccessible to proper scrutiny, so that we are now obliged to disregard them. The remaining data showed no benefit for oseltamivir against complications (fig 6).

Evidence on harms of neuraminidase inhibitors:

Two of the studies excluded for addressing the benefits of neuraminidase inhibitors question nevertheless
The data suggest an incidence of neuropsychiatric adverse events per 1000 adults aged 18-49 of 20-27 at 14 days and 30-40 at 30 days, and for neuropsychiatric adverse events in prospective clinical trials, an incidence of 0.5%. AERS includes 2275 adverse event reports for oseltamivir and 453 for zanamivir (excluding follow-up reports on the same individual event) generated worldwide between December 1999 and July 2009 (the month our request was answered). Unfortunately it indicates neither reporting country nor how long the event occurred before receipt of the report by the FDA. The period from 2004 onwards overlaps with AERS-2, which has reports from January 2004 to March 2009, indicating both initial and follow-up reports, and reporting the date of the adverse event. From July 2005 it indicates the reporting country. From July 2005 to March 2009, 1205 initial adverse events occurred. Most (681, 56.5%) were reported from Japan, followed by the United States (390, 32.4%). Most (1109, 92.0%) were for oseltamivir (perhaps reflecting its higher use). A disproportionate amount of reports are for people aged less than 20 (with data on age missing for many).

**DISCUSSION**

The data suggest that neuraminidase inhibitors are effective at reducing the symptoms of influenza. The evidence is of modest benefit—reduction of illness by about one day. This benefit has been generalised to assume benefits for very ill people in hospital. This seems reasonable, although it is worth remembering that we have no data to support this, and it is unlikely that ethics committees would allow a trial of no treatment for people with influenza who have life-threatening disease.

**Summary of databases on adverse effects of neuraminidase inhibitors**

<table>
<thead>
<tr>
<th>Data source</th>
<th>Who reports</th>
<th>What is reported</th>
<th>Date range of contents</th>
<th>Comments</th>
</tr>
</thead>
<tbody>
<tr>
<td>US FDA AERS-1 (obtained through Freedom of Information Act request)</td>
<td>Manufacturers under mandatory reporting requirements in accordance with FDA Code of Federal Regulations title 21 section 314.80; health professionals and consumers report voluntarily</td>
<td>Post-marketing surveillance adverse event reports occurring in US and abroad. For adverse events occurring in US, manufacturers must report to FDA all adverse events except for labelled non-serious events (assuming companies have been granted such a waiver). For non-US events, manufacturers are only required to report adverse events that are &quot;both serious and unexpected.&quot; For first three years after approval, FDA enters all adverse events into AERS database. After three years, all electronically submitted and all &quot;serious&quot; adverse events are entered into AERS</td>
<td>Aug 1999 (zanamivir) and Dec 1999 (oseltamivir) to Jul 2009</td>
<td>Date of event, timing in relation to drug, country of report unclear</td>
</tr>
<tr>
<td>US FDA AERS-2</td>
<td>Manufacturers under mandatory reporting requirements in accordance with FDA Code of Federal Regulations title 21 section 314.80; health professionals and consumers report voluntarily</td>
<td>Post-marketing surveillance adverse event reports occurring in US and abroad. For adverse events occurring in US, manufacturers must report to FDA all adverse events except for labelled non-serious events (assuming companies have been granted such a waiver). For non-US events, manufacturers are only required to report adverse events that are &quot;both serious and unexpected.&quot; For first three years after approval, FDA enters all adverse events into AERS database. After three years, all electronically submitted and all &quot;serious&quot; adverse events are entered into AERS</td>
<td>Jan 2004 to Mar 2009</td>
<td>More detailed reports indicating reporting country consistently from Jul 2005. Reporting of neuropsychiatric adverse events more common among children and adolescents taking oseltamivir, but relation to drug is unclear</td>
</tr>
<tr>
<td>Japanese Pharmaceuticals and Medical Devices Agency</td>
<td>Documents reviewed were submitted by Chugai Pharmaceutical to Japanese regulators in conjunction with new drug application for prophylactic use of Tamiflu 75mg capsules</td>
<td>Summary adverse events occurring in treatment trial protocol numbers WV15670, WV15671, and WV15730. Individual patient level description of serious adverse events occurring during these three trial protocols while receiving treatment (six participants), not receiving treatment (two participants), and resulting in early withdrawal (12 participants)</td>
<td>Event dates not given; using trial date rates, events occurred between Dec 1997 and Sep 1998</td>
<td>No cases of neuropsychiatric adverse events were reported in trials of otherwise healthy adults</td>
</tr>
</tbody>
</table>
confirmed influenza, based on study by Kaiser et al and three other studies (complications included pneumonia, bronchitis, otitis media, and sinusitis). Unpublished studies were included.

One important caveat to these results arises from concerns about the difference between efficacy (treatment response to pure influenza virus infection) and effectiveness (the real life response to influenza-like illness, when real cases of influenza are indistinguishable from other causative agents not responsive to neuraminidase inhibitors). Understanding the proportion of influenza-like illness caused by both seasonal and epidemic influenza is critical to generalising the results of this review to clinical practice. The finding of treatment effectiveness for the neuraminidase inhibitors may have been enhanced by the high percentage of influenza-like illness caused by influenza in most of the included trials—for example, up to 80%. Data on the effectiveness of oseltamivir against the complications of influenza are confusing. Hayashi pointed out that the original data, which led to the 2005 version of this original Cochrane review reporting benefits for oseltamivir on reduction of complications from lower respiratory tract infection, principally came from one meta-analysis that summarised 10 trials containing a mixture of published and unpublished data. Only two of the trials it contains are published (and are reported in this Cochrane review update), the remainder were offered to us under conditions we thought unacceptable, and what was offered to us was insufficient to analyse properly. (Comments on the Kaiser et al paper are in the web extra). This means we are now obliged to exclude the meta-analysis. The remaining published evidence is insufficient to answer the question about the effectiveness of either neuraminidase inhibitor on reducing the complications of lower respiratory tract infection, antibiotic use, or admissions to hospital. It is possible that there is a publication bias, especially as we know of eight trials that are unpublished and inaccessible. We have not undertaken a funnel plot because there are only three trials (fig 6), and so the issue of publication bias remains unresolved. Its direction might be in favour of exaggerating the treatment effect. Hayashi’s comments point out a serious problem with our original review, which we now address.

The results from the meta-analyses involving hazard ratios should be viewed with caution because of the approximate methods used to extract estimates for each study. Hazard ratios were rarely reported directly, so we had to use the ratio of the observed median duration of symptoms in each group as an approximation to the hazard ratio. This approach may be overly simplistic, as it makes a comparison at only one time point and assumes a constant survival difference over time, and thus may produce different meta-analysis results than if the actual hazard ratio estimates were available.

Role of neuraminidase inhibitors in seasonal influenza

Neuraminidase inhibitors had low effectiveness and high efficacy against symptoms (shortening the illness by half to one day, a crude estimate made by applying a hazard ratio of 1.2 on the control length of illness of four days to about 3.3 days, a reduction of less than one day, and preventing symptoms from appearing), and initially seemed to be well tolerated (with the possible exception of oseltamivir induced nausea and vomiting).

A surprising finding was the high percentage (57-80%) of influenza in the trial populations receiving neuraminidase inhibitors. We remain at a loss to explain this because most other data suggest much lower rates.

Role of neuraminidase inhibitors in pandemic influenza

We identified no direct comparative evidence of the role of neuraminidase inhibitors in avian influenza A/H5N1 or in the current novel influenza A/H1N1 pandemic. This means that we have to generalise from the trials, and this seems reasonable given that...
Evidence for or against serious adverse events is lacking, although oseltamivir causes nausea. Although laboratory confirmed influenza but not influenza-like illness Neuraminidase inhibitors reduce the chance of people exposed to influenza developing possible harms of neuraminidase inhibitors Neuraminidase inhibitors do not, however, prevent infection or stop nasal viral excretion, so they may be a suboptimal means of interrupting viral spread in a pandemic. If used to contain a severe pandemic outbreak, neuraminidase inhibitors should be considered only part of a package of measures to interrupt spread, including physical measures. Possible harms of neuraminidase inhibitors We focused on oseltamivir because of the considerably greater global experience with this drug. Post-marketing pharmacovigilance data about oseltamivir obtained from the FDA are of limited use because of likely under-representation of reports generated from outside the United States. The entire AERS database (containing adverse event reports of all types) between 1999 and 15 September 2007 contains only 1805 reports. However, the Roche global safety database contains reports of 2466 neuropsychiatric adverse events during this time, of which 562 (22.8%) were classified as “serious.” Another important limitation of the AERS database is the practice by the FDA of not registering non-electronically submitted reports of non-serious adverse events three years after a drug’s initial approval (personal correspondence with FDA, 14 October 2009). Our findings of a possible association with neuraminidase inhibitors and the onset of rare harms coming from the US AERS data accord with a review of phase IV evidence from eight cases (adolescents and adults), suggesting oseltamivir may induce sudden behavioural changes in recipients, including hallucination, suicidal tendencies, and sudden death while asleep. This evidence came soon after a review ordered by the Japanese government, in part triggered by the 567 serious neuropsychiatric cases received since the 2001 launch of the drug and May 2007. It is, however, estimated that more than 36 million doses have been prescribed since 2001, making such harms (even if confirmed) rare. We therefore found under-reported evidence of varied quality, which could not answer concerns about the toxicity of neuraminidase inhibitors, especially oseltamivir. Governments should set up studies to monitor the safety of neuraminidase inhibitors. Conclusion Because of the moderate effectiveness of neuraminidase inhibitors, we believe they should not be used in routine control of seasonal influenza. We are unsure of the generalisability of our conclusions from seasonal to pandemic influenza. Evidence on the effects of oseltamivir in complications from lower respiratory tract infections, reported in our 2006 Cochrane review, may be unreliable. Evidence on serious harms of neuraminidase inhibitors is limited. Independent randomised trials to resolve the uncertainties surrounding effectiveness are needed. We thank Liz Dooley, Dr Aoki, Jon Deeks, Carlo Di Pietrantonj, and Vittorio Demicheli for input and advice on earlier versions of this review; Liz Dooley, Janet Wale, John Bartlett, Sree Nar, Tom Fahy, Ruth Foxlee, and Alex Rivetti for help with the searches; and the Australian National Health and Medical Research Council and the UK NHS Research and Development fund for grants to enable this international rapid update. Funding: This study was supported by grants from the Australian National Health and Medical Research Council and the UK NHS Research and Development fund. Competing Interests: All authors have completed the Unified Competing Interest form at www.icmje.org/coi_disclosure.pdf (available on request from the corresponding author) and declare that (1) CDM and TOJ have support from the UK National Institute for Health Research and the Australian National Health and Medical Research Council for the submitted work; (2) CDM has provided expert advice to GlaxoSmithKline about vaccination against acute otitis media; (3) their spouses, partners, or children have no financial relationships that may be relevant to the submitted work; and (4) no authors have non-financial interests that may be relevant to the submitted work. Ethical approval: Not required.


Accepted: 26 November 2009